Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer
JAMA Surgery · 01.05.2026 · 161 (5) · 450
DOI: 10.1001/jamasurg.2026.0085 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Surgery, erschienen am 01.05.2026. Verfasst von Lars Henrik Jensen und 18 weiteren Autor:innen. Beteiligte Einrichtung: Danish Colorectal Cancer Center South, Oncology, University Hospital of Southern Denmark, Vejle Hospital, Vejle, Denmark. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Colonic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Colectomy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance Locally advanced colon cancer carries a high risk of recurrence. Neoadjuvant chemotherapy has been proposed to improve outcomes, but evidence from phase III trials remains limited.
Objective
To determine whether neoadjuvant chemotherapy improves disease-free survival (DFS) compared with upfront surgery in patients with locally advanced colon cancer. Design, Setting, and Participants This randomized, open-label, phase III clinical trial conducted from October 14, 2013, to November 27, 2020, with follow-up up to 3 years for DFS took place at 9 hospitals in Denmark, Norway, and Sweden. A total of 250 patients with locally advanced colon cancer staged by computed tomography, Eastern Cooperative Oncology Group performance status 0 to 2, and no distant metastases were enrolled. These data were analyzed from January 2024 to October 2024.
Interventions
Patients were randomized 1:1 to upfront surgery followed by adjuvant chemotherapy as indicated (n = 122) or 3 cycles of neoadjuvant capecitabine and oxaliplatin followed by surgery and adjuvant chemotherapy if indicated (n = 126). Main Outcomes and Measures The primary end point was DFS. Secondary end points included surgical and pathological outcomes, adjuvant chemotherapy use, adverse events, quality of life, and exploratory analysis by mismatch repair (MMR) status.
Results
A total of 248 patients were eligible and included in analyses (median age, 66 [min-max, 24-84] years; 111 women [45%] and 137 men [55%]). At 3 years, DFS was 87% in the upfront surgery arm and 83% in the neoadjuvant arm ( P = .36). Neoadjuvant chemotherapy was feasible and safe, achieved tumor downstaging, and reduced the proportion of patients meeting criteria for adjuvant chemotherapy (upfront surgery 73% vs neoadjuvant group 59%; P = .02). Exploratory analyses suggested variation by MMR status, with DFS estimates higher after upfront surgery in patients with MMR-deficient tumors. Postoperative complications, adverse event profiles, and quality of life were comparable between groups. Conclusions and Relevance Neoadjuvant chemotherapy did not improve DFS compared with upfront surgery, establishing the NeoCol trial as negative. However, feasibility, safety, downstaging effects, reduced adjuvant chemotherapy use, and MMR subgroup findings add to evidence from other randomized trials supporting further evaluation of this strategy in individualized management of locally advanced colon cancer. Trial Registration ClinicalTrials.gov Identifier: NCT01918527
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Danish Colorectal Cancer Center South, Oncology, University Hospital of Southern Denmark, Vejle Hospital, Vejle, Denmark.
- Gastro Unit, Surgical Section, Copenhagen University Hospital, Hvidovre, Copenhagen, Denmark.
- Institute for Clinical Medicine, Copenhagen University, Copenhagen, Denmark.
- Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
- Department of Oncology, Zealand University Hospital, Naestved, Denmark.
- Danish Colorectal Cancer Center South, Surgery, University Hospital of Southern Denmark, Vejle Hospital, Vejle, Denmark.
Zitieren
APA
Jensen, L. H., Kjaer, M., Diness, L. V., Hollânder, N. H., Rahr, H. B., Pfeffer, F., Larsen, F. O., Lindebjerg, J., Rafaelsen, S. R., Hansen, T. F., Timm, S., Løes, I. M., Gögenur, I., Zitnjak, D., Andersen, F., Petersen, L. N., Lindskog, E. B., Poulsen, L. Ø., & Dahl, O. (2026). Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer. JAMA Surgery, 161(5), 450. https://doi.org/10.1001/jamasurg.2026.0085
Vancouver
Jensen LH, Kjaer M, Diness LV, Hollânder NH, Rahr HB, Pfeffer F, et al. Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer. JAMA Surgery. 2026;161(5):450. doi:10.1001/jamasurg.2026.0085
BibTeX
@article{Jensen2026,
author = {Jensen, Lars Henrik and Kjaer, Monica and Diness, Laura Vittrup and Hollânder, Niels Henrik and Rahr, Hans Bjarke and Pfeffer, Frank and Larsen, Finn Ole and Lindebjerg, Jan and Rafaelsen, Søren Rafael and Hansen, Torben Frøstrup and Timm, Signe and Løes, Inger Marie and Gögenur, Ismail and Zitnjak, Daniela and Andersen, Fahimeh and Petersen, Lone Nørgård and Lindskog, Elinor Bexe and Poulsen, Laurids Østergaard and Dahl, Olav},
title = {Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer},
journal = {JAMA Surgery},
year = {2026},
volume = {161},
number = {5},
pages = {450},
doi = {10.1001/jamasurg.2026.0085}
}
EUVIMED